BlackRock’s Artiva Biotherapeutics ARTV Stock Holding History

BlackRock’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.74M	Buy	694,726 +481,338	+226%	+$4.38M	﹤0.01%	3837
2026 Q1	$1.37M	Buy	213,388 +850	+0.4%	+$4.2K	﹤0.01%	4235
2025 Q4	$912K	Sell	212,538 -81,884	-28%	-$309K	﹤0.01%	4328
2025 Q3	$845K	Sell	294,422 -191,305	-39%	-$512K	﹤0.01%	4332
2025 Q2	$733K	Sell	485,727 -759,784	-61%	-$1.6M	﹤0.01%	4352
2025 Q1	$3.74M	Buy	1,245,511 +199,158	+19%	+$1.08M	﹤0.01%	3755
2024 Q4	$10.5M	Buy	1,046,353 +208,740	+25%	+$2.51M	﹤0.01%	3399
2024 Q3	$12.9M	Buy	+837,613	New	+$9.71M	﹤0.01%	3275

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock's ARTV Position: Q2 2026 in Review

BlackRock increased its Artiva Biotherapeutics (ARTV) stake by 226% in Q2 2026, buying an estimated $4.38M and bringing the position to 694,726 shares worth $6.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3837.

BlackRock first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $12.9M in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

BlackRock held 694,726 shares of Artiva Biotherapeutics worth $6.74M as of Q2 2026.
BlackRock bought 481,338 Artiva Biotherapeutics shares in Q2 2026, an estimated $4.38M.
Artiva Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3837 holding.
BlackRock first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
BlackRock's Artiva Biotherapeutics position peaked at $12.9M in Q3 2024.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.